## BACKGROUND. The pretreatment serum prostate specific antigen level (PSAL) is the most significant predictor of biochemical and local failure in patients treated with definitive radiotherapy. The role of prostate specific antigen (PSA) density (PSAD) relative to PSAL for such patients is controv
Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma
β Scribed by Katherine L. Meyer-Siegler; Michael A. Bellino; Myron Tannenbaum
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 122 KB
- Volume
- 94
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
BACKGROUND
Cytokines are polypeptides that constitute a class of chemical mediator molecules that modulate cell growth by inducing specific target gene expression. The objective of this study was to evaluate the clinical usefulness of serum evaluation of the cytokine macrophage migration inhibitory factor (MIF) in patients undergoing routine prostate specific antigen (PSA) screening.
METHODS
In this preliminary, retrospective study, the authors report the development of an enzymeβlinked immunosorbent assay (ELISA) for MIF determination in serum samples. A polymerase chain reaction (PCR)βbased assay investigated associations between MIF expression and prostate carcinoma (CaP). The authors developed a relative quantitative reverse transcriptaseβPCR assay to determine MIF mRNA amounts within laserβcapture microscopy (LCM)βdissected prostate epithelial cells.
RESULTS
A comparison of serum MIF levels and total PSA levels identified a positive correlation (correlation coefficient [r2] = 0.61; P < 0.001; n = 509 patients), suggesting an association between elevated serum concentrations of these proteins and CaP. A correlation of serum MIF levels with a diagnosis of CaP demonstrated that patients with a previous CaP diagnosis had significantly elevated serum MIF concentrations (mean Β± standard deviation, 6.8 Β± 0.87 ng/mL; P < 0.001). To associate altered serum MIF levels with MIF mRNA expression within prostate epithelial cells, LCMβdissected prostate epithelial cells (formalin fixed biopsies from three different patients) were used to determine MIF mRNA amounts by PCR analysis. On average, MIF mRNA amounts were 6.5 times higher in CaP epithelial cells that were invasive to the margin compared with MIF mRNA amounts in normal prostate epithelial cells within the same biopsy specimen.
CONCLUSIONS
The ELISA data from the current study suggested an association between increased MIF expression and CaP and suggested that serum MIF concentration may serve as a prognostic marker for CaP. Cancer 2002;94:1449β56. Β© 2002 American Cancer Society.
DOI 10.1002/cncr.10354
π SIMILAR VOLUMES
tients with residual tumor in 1 or more biopsies at 10 -78 months of follow-up Regional Cancer Centre, Ottawa, Ontario, Canwere selected for review. All patients had undergone biopsy on more than one ada. occasion. The 198 biopsies were stained for PSA, high molecular weight keratin,
T1, 2, 3pN0, M0), 44 patients with BPH, and 54 healthy Charite Β΄, Humboldt University Berlin, Berlin, Gercontrols. Prostate volume was determined by transrectal ultrasound. many. ## RESULTS. The median values of t-PSA and f-PSA% were 7.8 mg/L and 10.5% in PCa patients, 4.3 mg/L and 20.8% in patie